In this RCT including survivors of breast cancer with GSM undergoing treatment with aromatase inhibitors, the subjective and objective outcomes of most participants in both groups improved in symptom severity, sexuality, and vaginal tissue characteristics at the 6-month follow-up . The gene discussed is CYP19A1; the disease is breast carcinoma.